| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 90 | 2024 | 166 | 12.320 |
Why?
|
| Prostatic Neoplasms | 85 | 2026 | 302 | 11.970 |
Why?
|
| Cystectomy | 76 | 2024 | 104 | 9.500 |
Why?
|
| Prostatectomy | 52 | 2026 | 90 | 6.730 |
Why?
|
| Carcinoma, Transitional Cell | 33 | 2023 | 56 | 4.050 |
Why?
|
| Urology | 12 | 2021 | 30 | 3.500 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 8 | 2020 | 11 | 3.450 |
Why?
|
| Male | 197 | 2026 | 13921 | 2.790 |
Why?
|
| Prostate-Specific Antigen | 23 | 2024 | 53 | 2.540 |
Why?
|
| Kidney Neoplasms | 22 | 2020 | 103 | 2.540 |
Why?
|
| Humans | 239 | 2026 | 28851 | 2.360 |
Why?
|
| Robotics | 11 | 2020 | 43 | 2.360 |
Why?
|
| Aged | 133 | 2026 | 5598 | 2.300 |
Why?
|
| Urinary Diversion | 20 | 2018 | 26 | 2.230 |
Why?
|
| Neoplasm Staging | 48 | 2023 | 480 | 2.180 |
Why?
|
| Neoplasm Recurrence, Local | 28 | 2021 | 347 | 2.150 |
Why?
|
| Androgen Antagonists | 12 | 2020 | 20 | 2.060 |
Why?
|
| Middle Aged | 136 | 2026 | 7414 | 2.030 |
Why?
|
| Prostate | 16 | 2020 | 52 | 1.940 |
Why?
|
| Nephrectomy | 16 | 2017 | 48 | 1.830 |
Why?
|
| Laparoscopy | 13 | 2014 | 156 | 1.800 |
Why?
|
| Postoperative Complications | 25 | 2019 | 634 | 1.720 |
Why?
|
| Neoadjuvant Therapy | 15 | 2026 | 80 | 1.570 |
Why?
|
| Blood Loss, Surgical | 15 | 2013 | 53 | 1.560 |
Why?
|
| Treatment Outcome | 55 | 2024 | 2426 | 1.540 |
Why?
|
| Neoplasm Invasiveness | 35 | 2024 | 190 | 1.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2026 | 433 | 1.460 |
Why?
|
| Medical Oncology | 4 | 2021 | 98 | 1.450 |
Why?
|
| Lymph Node Excision | 15 | 2014 | 101 | 1.450 |
Why?
|
| Carcinoma, Renal Cell | 14 | 2017 | 79 | 1.430 |
Why?
|
| Aged, 80 and over | 57 | 2024 | 2065 | 1.420 |
Why?
|
| Antineoplastic Agents | 9 | 2021 | 686 | 1.360 |
Why?
|
| Prognosis | 28 | 2020 | 811 | 1.300 |
Why?
|
| Retrospective Studies | 53 | 2023 | 2635 | 1.130 |
Why?
|
| Patient Preference | 2 | 2018 | 34 | 1.030 |
Why?
|
| Quality of Life | 9 | 2024 | 521 | 1.020 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 245 | 1.020 |
Why?
|
| Urinary Reservoirs, Continent | 9 | 2018 | 13 | 0.990 |
Why?
|
| Female | 87 | 2024 | 15624 | 0.910 |
Why?
|
| Carcinoma | 5 | 2014 | 74 | 0.880 |
Why?
|
| Robotic Surgical Procedures | 5 | 2019 | 51 | 0.860 |
Why?
|
| Ablation Techniques | 3 | 2020 | 13 | 0.860 |
Why?
|
| Adult | 65 | 2021 | 8024 | 0.860 |
Why?
|
| Carcinoma in Situ | 10 | 2024 | 46 | 0.850 |
Why?
|
| Chemotherapy, Adjuvant | 13 | 2026 | 118 | 0.830 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2020 | 29 | 0.820 |
Why?
|
| Length of Stay | 16 | 2014 | 245 | 0.790 |
Why?
|
| Urologic Neoplasms | 4 | 2017 | 13 | 0.790 |
Why?
|
| Germ-Line Mutation | 2 | 2020 | 31 | 0.780 |
Why?
|
| Blood Transfusion | 7 | 2013 | 77 | 0.770 |
Why?
|
| Lymph Nodes | 3 | 2012 | 103 | 0.770 |
Why?
|
| Genetic Testing | 2 | 2020 | 68 | 0.760 |
Why?
|
| Salvage Therapy | 5 | 2020 | 37 | 0.740 |
Why?
|
| Societies, Medical | 7 | 2021 | 93 | 0.720 |
Why?
|
| Disease Management | 3 | 2018 | 91 | 0.710 |
Why?
|
| United States | 22 | 2020 | 2222 | 0.700 |
Why?
|
| Biopsy, Needle | 11 | 2013 | 48 | 0.700 |
Why?
|
| Survival Rate | 22 | 2021 | 432 | 0.680 |
Why?
|
| Urologic Surgical Procedures | 3 | 2017 | 23 | 0.680 |
Why?
|
| Evidence-Based Medicine | 6 | 2021 | 146 | 0.670 |
Why?
|
| Androstenes | 2 | 2020 | 3 | 0.670 |
Why?
|
| Osteoporotic Fractures | 1 | 2020 | 5 | 0.670 |
Why?
|
| Prospective Studies | 30 | 2026 | 1280 | 0.670 |
Why?
|
| Follow-Up Studies | 29 | 2024 | 1032 | 0.660 |
Why?
|
| Urinary Bladder Diseases | 3 | 2013 | 9 | 0.650 |
Why?
|
| Osteoporosis | 1 | 2020 | 63 | 0.640 |
Why?
|
| BCG Vaccine | 6 | 2024 | 14 | 0.630 |
Why?
|
| Immunotherapy | 4 | 2024 | 163 | 0.610 |
Why?
|
| Nutritional Status | 2 | 2018 | 80 | 0.610 |
Why?
|
| Cohort Studies | 18 | 2021 | 897 | 0.560 |
Why?
|
| Algorithms | 3 | 2018 | 431 | 0.560 |
Why?
|
| Urologic Diseases | 1 | 2018 | 6 | 0.560 |
Why?
|
| Perioperative Care | 2 | 2019 | 35 | 0.560 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 63 | 0.560 |
Why?
|
| Neoplasm Grading | 7 | 2020 | 105 | 0.550 |
Why?
|
| Hospitals | 3 | 2020 | 77 | 0.520 |
Why?
|
| Disease Progression | 10 | 2020 | 477 | 0.510 |
Why?
|
| Clostridium Infections | 1 | 2017 | 67 | 0.510 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2020 | 170 | 0.490 |
Why?
|
| Survival Analysis | 8 | 2016 | 288 | 0.490 |
Why?
|
| Testicular Neoplasms | 3 | 2006 | 16 | 0.480 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2015 | 4 | 0.470 |
Why?
|
| Risk Factors | 27 | 2020 | 2126 | 0.450 |
Why?
|
| Time Factors | 18 | 2020 | 1613 | 0.450 |
Why?
|
| Body Mass Index | 7 | 2011 | 412 | 0.450 |
Why?
|
| Critical Pathways | 4 | 2005 | 16 | 0.450 |
Why?
|
| Patient Readmission | 4 | 2014 | 108 | 0.440 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2020 | 63 | 0.430 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2013 | 164 | 0.430 |
Why?
|
| Consensus | 5 | 2022 | 75 | 0.430 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2005 | 16 | 0.420 |
Why?
|
| Tumor Burden | 4 | 2013 | 110 | 0.420 |
Why?
|
| Vena Cava, Inferior | 2 | 2011 | 16 | 0.420 |
Why?
|
| Risk Assessment | 10 | 2018 | 631 | 0.400 |
Why?
|
| Osteoradionecrosis | 1 | 2013 | 1 | 0.400 |
Why?
|
| Pubic Bone | 1 | 2013 | 3 | 0.400 |
Why?
|
| Combined Modality Therapy | 8 | 2021 | 303 | 0.390 |
Why?
|
| Disease-Free Survival | 11 | 2018 | 236 | 0.390 |
Why?
|
| Biomarkers, Tumor | 8 | 2018 | 415 | 0.390 |
Why?
|
| Radiation Injuries | 1 | 2013 | 52 | 0.380 |
Why?
|
| Administration, Intravesical | 8 | 2024 | 16 | 0.380 |
Why?
|
| Fractures, Bone | 1 | 2013 | 46 | 0.380 |
Why?
|
| Multivariate Analysis | 10 | 2017 | 302 | 0.380 |
Why?
|
| Phenylthiohydantoin | 2 | 2026 | 8 | 0.370 |
Why?
|
| Biopsy | 4 | 2010 | 208 | 0.370 |
Why?
|
| Benzamides | 2 | 2026 | 39 | 0.370 |
Why?
|
| Early Detection of Cancer | 5 | 2024 | 137 | 0.360 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 11 | 0.360 |
Why?
|
| Equipment Failure | 1 | 2011 | 31 | 0.360 |
Why?
|
| Internship and Residency | 3 | 2017 | 250 | 0.360 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 15 | 0.360 |
Why?
|
| Dietary Supplements | 3 | 2019 | 272 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 676 | 0.340 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2018 | 26 | 0.330 |
Why?
|
| Neoplasms, Second Primary | 3 | 2009 | 21 | 0.320 |
Why?
|
| Urothelium | 4 | 2015 | 35 | 0.320 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 20 | 0.310 |
Why?
|
| Kidney | 3 | 2017 | 289 | 0.310 |
Why?
|
| Proportional Hazards Models | 10 | 2020 | 226 | 0.310 |
Why?
|
| Adenocarcinoma | 3 | 2020 | 300 | 0.310 |
Why?
|
| Physicians | 2 | 2012 | 83 | 0.310 |
Why?
|
| Cystoscopy | 4 | 2018 | 16 | 0.300 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 4 | 2011 | 10 | 0.300 |
Why?
|
| Sarcopenia | 2 | 2019 | 44 | 0.290 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2008 | 10 | 0.290 |
Why?
|
| Health Planning Councils | 1 | 2008 | 2 | 0.290 |
Why?
|
| Patient Selection | 7 | 2016 | 150 | 0.290 |
Why?
|
| Cystitis | 2 | 2013 | 11 | 0.290 |
Why?
|
| Erectile Dysfunction | 4 | 2007 | 15 | 0.280 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 2020 | 37 | 0.280 |
Why?
|
| Surveys and Questionnaires | 7 | 2014 | 997 | 0.280 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2007 | 2 | 0.270 |
Why?
|
| Age Factors | 10 | 2021 | 737 | 0.270 |
Why?
|
| Incidence | 11 | 2018 | 572 | 0.260 |
Why?
|
| Research Report | 2 | 2017 | 23 | 0.260 |
Why?
|
| Checklist | 2 | 2017 | 22 | 0.260 |
Why?
|
| Bone Marrow | 1 | 2007 | 83 | 0.250 |
Why?
|
| Adjuvants, Immunologic | 4 | 2024 | 68 | 0.250 |
Why?
|
| Predictive Value of Tests | 8 | 2014 | 485 | 0.250 |
Why?
|
| Urinary Incontinence | 3 | 2013 | 20 | 0.250 |
Why?
|
| Natural Orifice Endoscopic Surgery | 2 | 2016 | 9 | 0.240 |
Why?
|
| Testosterone | 2 | 2020 | 74 | 0.240 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 113 | 0.240 |
Why?
|
| Insurance, Health | 2 | 2017 | 51 | 0.240 |
Why?
|
| Quality Improvement | 2 | 2017 | 124 | 0.240 |
Why?
|
| Urethra | 4 | 2016 | 33 | 0.240 |
Why?
|
| Lymphatic Metastasis | 5 | 2012 | 126 | 0.230 |
Why?
|
| Prostatic Hyperplasia | 4 | 2010 | 9 | 0.230 |
Why?
|
| Ureteral Obstruction | 2 | 2009 | 12 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2015 | 194 | 0.220 |
Why?
|
| Abdominal Neoplasms | 1 | 2004 | 1 | 0.220 |
Why?
|
| Pelvic Neoplasms | 1 | 2004 | 8 | 0.220 |
Why?
|
| Adenoviridae | 2 | 2024 | 68 | 0.220 |
Why?
|
| Carcinoid Tumor | 1 | 2004 | 3 | 0.210 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 2 | 2015 | 2 | 0.210 |
Why?
|
| Smartphone | 1 | 2024 | 75 | 0.210 |
Why?
|
| Mobile Applications | 1 | 2024 | 80 | 0.210 |
Why?
|
| Specimen Handling | 3 | 2013 | 33 | 0.200 |
Why?
|
| Ureteral Neoplasms | 2 | 2020 | 6 | 0.200 |
Why?
|
| Surgical Staplers | 1 | 2003 | 2 | 0.200 |
Why?
|
| Hemostasis, Surgical | 1 | 2003 | 7 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 402 | 0.190 |
Why?
|
| African Americans | 3 | 2012 | 352 | 0.190 |
Why?
|
| Taxoids | 2 | 2016 | 37 | 0.190 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2002 | 3 | 0.190 |
Why?
|
| Nitriles | 2 | 2026 | 38 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 77 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 218 | 0.190 |
Why?
|
| Mitomycin | 1 | 2002 | 19 | 0.190 |
Why?
|
| Eosinophilia | 1 | 2002 | 8 | 0.190 |
Why?
|
| Urination | 2 | 2012 | 13 | 0.190 |
Why?
|
| Decision Making | 2 | 2018 | 178 | 0.180 |
Why?
|
| Lymphoma, Follicular | 1 | 2002 | 13 | 0.180 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 32 | 0.180 |
Why?
|
| Lidocaine | 1 | 2001 | 27 | 0.180 |
Why?
|
| Lymphoma, B-Cell | 1 | 2002 | 19 | 0.180 |
Why?
|
| Patient Discharge | 2 | 2014 | 109 | 0.180 |
Why?
|
| Anesthetics, Local | 1 | 2001 | 12 | 0.180 |
Why?
|
| Pelvis | 3 | 2011 | 38 | 0.180 |
Why?
|
| Genital Neoplasms, Female | 1 | 2002 | 67 | 0.180 |
Why?
|
| Aminolevulinic Acid | 2 | 2014 | 14 | 0.180 |
Why?
|
| Urinary Bladder | 5 | 2014 | 119 | 0.180 |
Why?
|
| Infertility, Male | 2 | 2006 | 23 | 0.170 |
Why?
|
| Models, Organizational | 1 | 2021 | 18 | 0.170 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 16 | 0.170 |
Why?
|
| Recurrence | 3 | 2012 | 326 | 0.170 |
Why?
|
| Malnutrition | 2 | 2011 | 31 | 0.170 |
Why?
|
| Muscle, Smooth | 3 | 2014 | 41 | 0.170 |
Why?
|
| Cysts | 2 | 2007 | 23 | 0.170 |
Why?
|
| Leuprolide | 1 | 2020 | 5 | 0.160 |
Why?
|
| Endometrial Neoplasms | 1 | 2002 | 189 | 0.160 |
Why?
|
| Pyrimidinones | 1 | 2020 | 16 | 0.160 |
Why?
|
| Phenylurea Compounds | 1 | 2020 | 17 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2020 | 14 | 0.160 |
Why?
|
| Genetic Vectors | 1 | 2020 | 118 | 0.160 |
Why?
|
| Seminal Vesicles | 1 | 2020 | 5 | 0.160 |
Why?
|
| Lysosomes | 1 | 2020 | 56 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 472 | 0.160 |
Why?
|
| Parkinson Disease | 1 | 2020 | 47 | 0.160 |
Why?
|
| Genetic Therapy | 1 | 2020 | 124 | 0.160 |
Why?
|
| Ureteral Diseases | 1 | 1999 | 1 | 0.150 |
Why?
|
| Kidney Pelvis | 1 | 1999 | 5 | 0.150 |
Why?
|
| Adolescent | 9 | 2014 | 3193 | 0.150 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 164 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 90 | 0.150 |
Why?
|
| Abiraterone Acetate | 1 | 2018 | 2 | 0.150 |
Why?
|
| Orchiectomy | 2 | 2020 | 12 | 0.150 |
Why?
|
| Population Dynamics | 1 | 2018 | 30 | 0.140 |
Why?
|
| Neutrophils | 1 | 2019 | 183 | 0.140 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2017 | 81 | 0.140 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 11 | 0.140 |
Why?
|
| Urinalysis | 1 | 2018 | 11 | 0.140 |
Why?
|
| Cisplatin | 4 | 2022 | 186 | 0.140 |
Why?
|
| Intestines | 2 | 2012 | 118 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 481 | 0.140 |
Why?
|
| Perioperative Period | 1 | 2018 | 7 | 0.140 |
Why?
|
| Reproducibility of Results | 6 | 2014 | 787 | 0.140 |
Why?
|
| Sensitivity and Specificity | 5 | 2009 | 524 | 0.140 |
Why?
|
| Tobacco Smoking | 1 | 2018 | 38 | 0.140 |
Why?
|
| Androstane-3,17-diol | 1 | 2017 | 9 | 0.140 |
Why?
|
| Anabolic Agents | 1 | 2017 | 12 | 0.140 |
Why?
|
| Urologists | 1 | 2017 | 5 | 0.140 |
Why?
|
| Aldo-Keto Reductase Family 1 Member C3 | 1 | 2017 | 21 | 0.140 |
Why?
|
| Receptors, GABA-A | 1 | 2017 | 18 | 0.140 |
Why?
|
| Databases, Factual | 5 | 2017 | 268 | 0.140 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 9 | 0.140 |
Why?
|
| Insurance Coverage | 1 | 2017 | 31 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 66 | 0.130 |
Why?
|
| Pain, Postoperative | 3 | 2007 | 62 | 0.130 |
Why?
|
| Postoperative Care | 3 | 2007 | 68 | 0.130 |
Why?
|
| Comorbidity | 4 | 2014 | 261 | 0.130 |
Why?
|
| Urethral Neoplasms | 2 | 2009 | 3 | 0.130 |
Why?
|
| Remission Induction | 1 | 2017 | 58 | 0.130 |
Why?
|
| Glutathione Transferase | 1 | 1997 | 33 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 165 | 0.130 |
Why?
|
| Hematocrit | 2 | 2010 | 26 | 0.130 |
Why?
|
| Hydronephrosis | 3 | 2020 | 11 | 0.130 |
Why?
|
| Androstenols | 1 | 2016 | 2 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 224 | 0.130 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 49 | 0.130 |
Why?
|
| Mitochondria | 1 | 2020 | 408 | 0.130 |
Why?
|
| Reoperation | 1 | 2017 | 153 | 0.120 |
Why?
|
| Receptors, Androgen | 2 | 2006 | 26 | 0.120 |
Why?
|
| Logistic Models | 5 | 2012 | 410 | 0.120 |
Why?
|
| Quality of Health Care | 2 | 2013 | 83 | 0.120 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 74 | 0.120 |
Why?
|
| Anastomosis, Surgical | 4 | 2012 | 38 | 0.110 |
Why?
|
| Research Design | 3 | 2018 | 187 | 0.110 |
Why?
|
| Organ Size | 3 | 2011 | 88 | 0.110 |
Why?
|
| Rectum | 3 | 2001 | 50 | 0.110 |
Why?
|
| Translations | 1 | 2014 | 2 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 187 | 0.110 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 465 | 0.110 |
Why?
|
| Urinary Tract | 1 | 2014 | 3 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 249 | 0.110 |
Why?
|
| Semen | 1 | 1995 | 29 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2007 | 379 | 0.110 |
Why?
|
| RNA, Messenger | 1 | 2017 | 668 | 0.110 |
Why?
|
| Forecasting | 1 | 2014 | 76 | 0.110 |
Why?
|
| Photosensitizing Agents | 1 | 2014 | 35 | 0.110 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 2 | 0.110 |
Why?
|
| Antibodies | 1 | 1995 | 125 | 0.110 |
Why?
|
| Tennessee | 6 | 2014 | 27 | 0.110 |
Why?
|
| Income | 1 | 2014 | 38 | 0.100 |
Why?
|
| Postoperative Period | 2 | 2012 | 68 | 0.100 |
Why?
|
| Young Adult | 4 | 2018 | 2833 | 0.100 |
Why?
|
| Child Health Services | 1 | 2013 | 7 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 15 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2017 | 824 | 0.100 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 38 | 0.100 |
Why?
|
| Pathology | 1 | 2013 | 8 | 0.100 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2013 | 7 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 19 | 0.100 |
Why?
|
| Penis | 1 | 1993 | 17 | 0.100 |
Why?
|
| Prevalence | 3 | 2019 | 518 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2018 | 415 | 0.100 |
Why?
|
| Pelvic Pain | 1 | 2013 | 10 | 0.100 |
Why?
|
| Hematuria | 1 | 2013 | 10 | 0.100 |
Why?
|
| Psychometrics | 3 | 2014 | 122 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2013 | 86 | 0.100 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2005 | 26 | 0.100 |
Why?
|
| Osteomyelitis | 1 | 2013 | 14 | 0.100 |
Why?
|
| Microsurgery | 1 | 1993 | 50 | 0.100 |
Why?
|
| Hospitals, High-Volume | 1 | 2012 | 8 | 0.100 |
Why?
|
| ABO Blood-Group System | 1 | 2012 | 7 | 0.100 |
Why?
|
| Organ Sparing Treatments | 1 | 2012 | 2 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2013 | 115 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 2013 | 39 | 0.100 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 21 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 97 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2024 | 463 | 0.100 |
Why?
|
| Palliative Care | 2 | 2011 | 86 | 0.090 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 21 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 120 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 607 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 50 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 122 | 0.090 |
Why?
|
| Antibodies, Heterophile | 1 | 2011 | 3 | 0.090 |
Why?
|
| Incidental Findings | 1 | 2011 | 13 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2020 | 739 | 0.090 |
Why?
|
| Lymphocele | 1 | 2011 | 2 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 639 | 0.090 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2011 | 4 | 0.090 |
Why?
|
| Lymphedema | 1 | 2011 | 15 | 0.090 |
Why?
|
| Dissection | 1 | 2011 | 20 | 0.090 |
Why?
|
| F2-Isoprostanes | 1 | 2011 | 2 | 0.090 |
Why?
|
| Muscles | 2 | 2022 | 73 | 0.090 |
Why?
|
| Ileus | 1 | 2011 | 7 | 0.090 |
Why?
|
| Vascular System Injuries | 1 | 2011 | 19 | 0.090 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2011 | 11 | 0.090 |
Why?
|
| Probability | 2 | 2009 | 78 | 0.090 |
Why?
|
| Single-Blind Method | 2 | 2018 | 46 | 0.090 |
Why?
|
| Elective Surgical Procedures | 1 | 2011 | 74 | 0.090 |
Why?
|
| Obesity | 2 | 2007 | 699 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 191 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2011 | 128 | 0.080 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 98 | 0.080 |
Why?
|
| History, 20th Century | 2 | 2021 | 84 | 0.080 |
Why?
|
| Flutamide | 3 | 2006 | 6 | 0.080 |
Why?
|
| Monitoring, Physiologic | 2 | 2018 | 58 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 126 | 0.080 |
Why?
|
| Congresses as Topic | 1 | 2010 | 35 | 0.080 |
Why?
|
| Telemedicine | 2 | 2024 | 200 | 0.080 |
Why?
|
| Prostatic Diseases | 1 | 2009 | 3 | 0.080 |
Why?
|
| Pain Measurement | 2 | 2007 | 172 | 0.080 |
Why?
|
| Health Facility Size | 1 | 2009 | 3 | 0.080 |
Why?
|
| Surgery Department, Hospital | 1 | 2009 | 13 | 0.080 |
Why?
|
| Feasibility Studies | 3 | 2006 | 222 | 0.080 |
Why?
|
| Sutures | 2 | 2013 | 15 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2020 | 190 | 0.080 |
Why?
|
| Hospital Mortality | 4 | 2012 | 159 | 0.070 |
Why?
|
| Early Diagnosis | 2 | 2007 | 32 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2008 | 17 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2008 | 11 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2008 | 39 | 0.070 |
Why?
|
| Endoscopy | 1 | 2009 | 57 | 0.070 |
Why?
|
| Chi-Square Distribution | 4 | 2012 | 145 | 0.070 |
Why?
|
| Observation | 1 | 2008 | 5 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 78 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 15 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2014 | 237 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 97 | 0.070 |
Why?
|
| Vinblastine | 2 | 2020 | 6 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 53 | 0.070 |
Why?
|
| Aspirin | 1 | 2009 | 125 | 0.070 |
Why?
|
| Methotrexate | 2 | 2020 | 36 | 0.070 |
Why?
|
| C-Peptide | 1 | 2007 | 8 | 0.070 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2007 | 4 | 0.070 |
Why?
|
| Urination Disorders | 1 | 2007 | 9 | 0.070 |
Why?
|
| Risk | 3 | 2014 | 138 | 0.070 |
Why?
|
| Urethral Stricture | 1 | 2007 | 7 | 0.070 |
Why?
|
| Doxorubicin | 2 | 2020 | 77 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2020 | 67 | 0.070 |
Why?
|
| Azasteroids | 1 | 2007 | 1 | 0.070 |
Why?
|
| Glycated Hemoglobin A | 1 | 2007 | 64 | 0.070 |
Why?
|
| Carbon Radioisotopes | 1 | 2007 | 20 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 52 | 0.070 |
Why?
|
| Leptin | 1 | 2007 | 67 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2021 | 15 | 0.070 |
Why?
|
| Goserelin | 2 | 1997 | 2 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2007 | 76 | 0.070 |
Why?
|
| Proctitis | 1 | 2006 | 1 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2007 | 73 | 0.060 |
Why?
|
| Retroperitoneal Space | 2 | 2007 | 9 | 0.060 |
Why?
|
| Sperm Banks | 1 | 2006 | 1 | 0.060 |
Why?
|
| Body Size | 1 | 2006 | 37 | 0.060 |
Why?
|
| Intensive Care Units | 2 | 2009 | 50 | 0.060 |
Why?
|
| Palpation | 2 | 1997 | 7 | 0.060 |
Why?
|
| Diarrhea | 1 | 2006 | 57 | 0.060 |
Why?
|
| Haplotypes | 2 | 2020 | 284 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2011 | 677 | 0.060 |
Why?
|
| Body Height | 1 | 2006 | 57 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2006 | 23 | 0.060 |
Why?
|
| Femoral Nerve | 1 | 2006 | 2 | 0.060 |
Why?
|
| Sex Factors | 3 | 2020 | 467 | 0.060 |
Why?
|
| Androgens | 1 | 2006 | 47 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2026 | 32 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 251 | 0.060 |
Why?
|
| Laparoscopes | 1 | 2005 | 3 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 841 | 0.060 |
Why?
|
| Renal Veins | 1 | 2005 | 7 | 0.060 |
Why?
|
| Thrombectomy | 1 | 2005 | 30 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2007 | 422 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2017 | 211 | 0.060 |
Why?
|
| Surgical Stomas | 1 | 2004 | 6 | 0.060 |
Why?
|
| Ureter | 1 | 2004 | 8 | 0.050 |
Why?
|
| Ileum | 1 | 2004 | 26 | 0.050 |
Why?
|
| Penile Neoplasms | 1 | 2004 | 12 | 0.050 |
Why?
|
| Intestinal Diseases | 1 | 2004 | 11 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2004 | 21 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2006 | 265 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2000 | 243 | 0.050 |
Why?
|
| Sickness Impact Profile | 1 | 2003 | 4 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 285 | 0.050 |
Why?
|
| Registries | 2 | 2017 | 396 | 0.050 |
Why?
|
| Health Surveys | 1 | 2003 | 85 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2017 | 1469 | 0.050 |
Why?
|
| Anesthesia | 1 | 2003 | 26 | 0.050 |
Why?
|
| Pelvic Exenteration | 1 | 2002 | 2 | 0.050 |
Why?
|
| Genitalia, Female | 1 | 2002 | 6 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 314 | 0.050 |
Why?
|
| Preoperative Care | 3 | 1997 | 81 | 0.050 |
Why?
|
| Vagina | 1 | 2002 | 42 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 194 | 0.050 |
Why?
|
| Carboplatin | 1 | 2022 | 121 | 0.050 |
Why?
|
| Administration, Rectal | 1 | 2001 | 5 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2002 | 86 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 303 | 0.040 |
Why?
|
| Cost Control | 1 | 2021 | 9 | 0.040 |
Why?
|
| Value-Based Purchasing | 1 | 2021 | 3 | 0.040 |
Why?
|
| Constriction, Pathologic | 2 | 2012 | 36 | 0.040 |
Why?
|
| Nephroureterectomy | 1 | 2020 | 1 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 49 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 12 | 0.040 |
Why?
|
| Health Status | 1 | 2001 | 149 | 0.040 |
Why?
|
| Paraparesis, Spastic | 1 | 2000 | 1 | 0.040 |
Why?
|
| Nomograms | 1 | 2020 | 9 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2020 | 13 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 59 | 0.040 |
Why?
|
| Community Networks | 1 | 2020 | 10 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 60 | 0.040 |
Why?
|
| Protective Factors | 1 | 2020 | 16 | 0.040 |
Why?
|
| Dopaminergic Neurons | 1 | 2020 | 19 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2000 | 50 | 0.040 |
Why?
|
| Heterozygote | 1 | 2020 | 69 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2020 | 108 | 0.040 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2014 | 15 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2020 | 77 | 0.040 |
Why?
|
| Ureteroscopy | 1 | 1999 | 5 | 0.040 |
Why?
|
| Mutation | 2 | 2020 | 867 | 0.040 |
Why?
|
| Urography | 1 | 1999 | 12 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2014 | 404 | 0.040 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2018 | 7 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 237 | 0.040 |
Why?
|
| Narrow Band Imaging | 1 | 2018 | 1 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2018 | 53 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2018 | 18 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 151 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1999 | 274 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 465 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 19 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2017 | 100 | 0.030 |
Why?
|
| American Cancer Society | 1 | 2017 | 4 | 0.030 |
Why?
|
| Aurora Kinase A | 1 | 2017 | 3 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 1997 | 39 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2013 | 1173 | 0.030 |
Why?
|
| Epithelium | 1 | 1997 | 40 | 0.030 |
Why?
|
| Counseling | 2 | 2007 | 57 | 0.030 |
Why?
|
| Brachytherapy | 2 | 2007 | 54 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 55 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 1997 | 57 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 377 | 0.030 |
Why?
|
| Selection Bias | 2 | 2010 | 13 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2017 | 152 | 0.030 |
Why?
|
| Keratin-14 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2015 | 24 | 0.030 |
Why?
|
| Linguistics | 1 | 2014 | 4 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2014 | 11 | 0.030 |
Why?
|
| Sperm Motility | 1 | 1995 | 16 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 23 | 0.030 |
Why?
|
| North America | 1 | 2014 | 41 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 137 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 194 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 99 | 0.030 |
Why?
|
| Embryonic Stem Cells | 1 | 2014 | 8 | 0.030 |
Why?
|
| Child | 3 | 2013 | 2287 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2015 | 173 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2014 | 39 | 0.030 |
Why?
|
| Diethylstilbestrol | 1 | 1994 | 2 | 0.030 |
Why?
|
| Urodynamics | 1 | 1994 | 5 | 0.030 |
Why?
|
| Maryland | 1 | 2013 | 7 | 0.030 |
Why?
|
| New York | 1 | 2013 | 17 | 0.030 |
Why?
|
| Oklahoma | 1 | 2017 | 1052 | 0.030 |
Why?
|
| Adrenalectomy | 1 | 1994 | 13 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2014 | 49 | 0.030 |
Why?
|
| Mice | 2 | 2015 | 4802 | 0.030 |
Why?
|
| Florida | 1 | 2013 | 55 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2014 | 71 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 39 | 0.030 |
Why?
|
| Neural Tube Defects | 1 | 1994 | 20 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 56 | 0.030 |
Why?
|
| Estrogens | 1 | 1994 | 56 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2006 | 93 | 0.030 |
Why?
|
| Databases, Bibliographic | 1 | 2013 | 10 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2014 | 138 | 0.030 |
Why?
|
| Transcriptome | 1 | 2015 | 231 | 0.030 |
Why?
|
| Veins | 1 | 1993 | 19 | 0.020 |
Why?
|
| Penile Erection | 1 | 1993 | 3 | 0.020 |
Why?
|
| Constriction | 1 | 1993 | 14 | 0.020 |
Why?
|
| Vacuum | 1 | 1993 | 11 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 354 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 120 | 0.020 |
Why?
|
| Infant | 2 | 2013 | 1025 | 0.020 |
Why?
|
| Equipment and Supplies | 1 | 1993 | 12 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 64 | 0.020 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1993 | 64 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 461 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2013 | 66 | 0.020 |
Why?
|
| Arteries | 1 | 1993 | 66 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2014 | 245 | 0.020 |
Why?
|
| SEER Program | 1 | 2012 | 47 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 376 | 0.020 |
Why?
|
| Cadherins | 1 | 2012 | 24 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 1993 | 96 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 60 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 427 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 90 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 874 | 0.020 |
Why?
|
| Medicare | 1 | 2012 | 126 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2011 | 31 | 0.020 |
Why?
|
| Spinal Cord | 1 | 1994 | 214 | 0.020 |
Why?
|
| Drug Implants | 1 | 2011 | 14 | 0.020 |
Why?
|
| Mass Screening | 1 | 2013 | 158 | 0.020 |
Why?
|
| Pneumonia, Aspiration | 1 | 2011 | 4 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2012 | 123 | 0.020 |
Why?
|
| Gastrointestinal Motility | 1 | 2011 | 30 | 0.020 |
Why?
|
| Digital Rectal Examination | 1 | 2010 | 3 | 0.020 |
Why?
|
| Microtomy | 1 | 2010 | 2 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 35 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 83 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 82 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 22 | 0.020 |
Why?
|
| Animals | 2 | 2015 | 10684 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 1507 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2010 | 95 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 93 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 995 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 200 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 1588 | 0.020 |
Why?
|
| False Negative Reactions | 2 | 1998 | 24 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 203 | 0.020 |
Why?
|
| Urinary Catheterization | 1 | 2007 | 15 | 0.020 |
Why?
|
| Adiponectin | 1 | 2007 | 29 | 0.020 |
Why?
|
| Angiomyolipoma | 1 | 2007 | 2 | 0.020 |
Why?
|
| Awards and Prizes | 1 | 2007 | 9 | 0.020 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2007 | 5 | 0.020 |
Why?
|
| Radioisotope Teletherapy | 1 | 2007 | 1 | 0.020 |
Why?
|
| Dutasteride | 1 | 2007 | 1 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2007 | 18 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 776 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2007 | 66 | 0.020 |
Why?
|
| Accreditation | 1 | 2007 | 36 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2007 | 33 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2006 | 9 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2006 | 4 | 0.020 |
Why?
|
| Abdomen | 1 | 2006 | 41 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2007 | 80 | 0.020 |
Why?
|
| Protein Deglycase DJ-1 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Global Health | 1 | 2007 | 54 | 0.020 |
Why?
|
| Drug Stability | 1 | 2006 | 23 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2006 | 40 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2006 | 94 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 107 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 116 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2006 | 89 | 0.020 |
Why?
|
| Ketorolac | 1 | 2005 | 9 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 328 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 319 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2007 | 235 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 102 | 0.010 |
Why?
|
| Cause of Death | 1 | 2005 | 73 | 0.010 |
Why?
|
| Curriculum | 1 | 2007 | 303 | 0.010 |
Why?
|
| Early Ambulation | 1 | 2004 | 3 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 417 | 0.010 |
Why?
|
| Bandages | 1 | 2004 | 14 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2003 | 31 | 0.010 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2002 | 4 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 1350 | 0.010 |
Why?
|
| Spastin | 1 | 2000 | 1 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2000 | 7 | 0.010 |
Why?
|
| England | 1 | 2000 | 39 | 0.010 |
Why?
|
| Pedigree | 1 | 2000 | 155 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2000 | 95 | 0.010 |
Why?
|
| Phenotype | 1 | 2000 | 685 | 0.010 |
Why?
|
| Smoking | 1 | 2002 | 477 | 0.010 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 1997 | 2 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 209 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 270 | 0.010 |
Why?
|
| Brain | 1 | 2000 | 769 | 0.010 |
Why?
|
| Compliance | 1 | 1994 | 21 | 0.010 |
Why?
|
| Pressure | 1 | 1994 | 90 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1994 | 916 | 0.010 |
Why?
|